RecruitingNCT06924359
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Sponsor
Peking University First Hospital
Enrollment
200 participants
Start Date
Mar 19, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
Eligibility
Min Age: 50 Years
Inclusion Criteria3
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
Exclusion Criteria3
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.
Interventions
DIAGNOSTIC_TESTMultimodal Ophthalmic Imaging and plasma biomarker
Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06924359
Related Trials
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
NCT069221881 location
Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study
NCT069531671 location
Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)
NCT069650621 location
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
NCT069956381 location
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
NCT072071221 location